Interleukin-1–Receptor Antagonist in Type 2 Diabetes Mellitus
Top Cited Papers
Open Access
- 12 April 2007
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 356 (15), 1517-1526
- https://doi.org/10.1056/nejmoa065213
Abstract
The expression of interleukin-1–receptor antagonist is reduced in pancreatic islets of patients with type 2 diabetes mellitus, and high glucose concentrations induce the production of interleukin-1β in human pancreatic beta cells, leading to impaired insulin secretion, decreased cell proliferation, and apoptosis.Keywords
This publication has 29 references indexed in Scilit:
- Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β InhibitionNew England Journal of Medicine, 2006
- The many worlds of reducing interleukin‐1Arthritis & Rheumatism, 2005
- Use and Abuse of HOMA ModelingDiabetes Care, 2004
- PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetesNature Genetics, 2003
- The Role of the Interleukin-1–Receptor Antagonist in Blocking Inflammation Mediated by Interleukin-1New England Journal of Medicine, 2000
- U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study GroupDiabetes, 1995
- Multiple defects of both hepatic and peripheral intracellular glucose processing contribute to the hyperglycaemia of NIDDMDiabetologia, 1995
- Cytotoxicity of Human p I 7 Interleukin-1 for Pancreatic Islets of LangerhansScience, 1986
- ELISA for human proinsulinClinica Chimica Acta; International Journal of Clinical Chemistry, 1986
- Radioimmunological determination of human C-peptide in serumDiabetologia, 1975